Loading organizations...
§ Private Profile · San Diego, CA, USA
Gene therapy developer creating AAV vector-based treatments for neurodegenerative disorders like Alzheimer's and Parkinson's.
Co-founded in January 2001 by Sherwin, San Diego, California-based Ceregene develops adeno-associated virus vector gene therapies designed to treat neurodegenerative disorders by delivering growth factors directly to the nervous system. The biotechnology company initially secured venture capital backing from lead investors including Alta Partners and MPM Capital to advance its clinical pipeline for Alzheimer's and Parkinson's diseases. In partnership with UC San Diego, the enterprise received a $5.4 million grant from the National Institutes of Health to fund Phase 2 clinical trials, safely treating over 115 subjects across four separate studies. The firm also acquired exclusive worldwide rights to specific nerve growth factors from Genentech before being fully acquired by Sangamo BioSciences. This acquisition agreement included the issuance of 100,000 shares of common stock to existing stockholders alongside contingent earn-out payments tied to future commercial revenues.
Ceregene has raised $39.6M across 2 funding rounds.
Ceregene has raised $39.6M in total across 2 funding rounds.
Ceregene has raised $39.6M across 2 funding rounds. Most recently, it raised $11.5M Series D in November 2010.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 11, 2010 | $11.5M Series D | Alta Partners, Kerry Dance | Investor Growth Capital, MPM Capital | Announced |
| Jun 27, 2007 | $28.1M Venture Round | — | Alta Partners, California Technology Ventures, Cell Genesys, Genzyme, Hamilton BioVentures, Investor Growth Capital, MPM Capital | Announced |
Ceregene has raised $39.6M in total across 2 funding rounds.
Ceregene's investors include Alta Partners, Kerry Dance, Investor Growth Capital, MPM Capital, California Technology Ventures, Cell Genesys, Genzyme, Hamilton BioVentures.